Alon Kushnir, RedDress CEO
Chronic wound biotech raises $26M in Series D to expand blood clot products
Wound care company RedDress, whose products heal chronic wounds using the patient’s own blood, has raised $26 million in a Series D funding round. The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
